CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 3,260 target
Drug / intervention
Intensive medical therapy +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00007657
NCT00007657Phase 3Completed
CompareCT.gov

CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation

US Department of Veterans Affairs·interventional·Posted Jan 4, 2001·Updated Jun 15, 2009

In Brief

A Phase 3 clinical trial evaluating Intensive medical therapy and Percutaneous Coronary Intervention (PCI) plus intensive medical therapy for Myocardial Ischemia. Completed, enrolled 3,260 participants across 48 sites in 2 countries.

Detailed Summary

PCI (optimal catheter-based coronary revascularization) + intensive medical therapy is superior to intensive medical therapy alone using the combined endpoint of all-cause mortality or nonfatal MI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Ischemia
CountriesCanada, United States
CollaboratorsMedical Research Council of Canada, Merck Sharp & Dohme LLC, Pfizer, GE Healthcare, Bristol-Myers Squibb, Astellas Pharma Inc, AstraZeneca, Sanofi, Datascope Corp., First Horizon, Kos, Key Pharmaceuticals, Integrated Therapeutics Group, Hoest-Marion-Roussel

Timeline

Phase 3CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 4, 2001
Enrollment StartDec 1, 1998
Study CompletionJun 1, 2006
TodayJul 2, 2026
Posted 25.5 years ago

Interventions

Intensive medical therapyprocedure

Percutaneous Coronary Intervention (PCI) plus intensive medical therapyprocedure